BR112017005314A2 - inibidores de ssao derivados de imidazo[4,5-c]piridina - Google Patents

inibidores de ssao derivados de imidazo[4,5-c]piridina

Info

Publication number
BR112017005314A2
BR112017005314A2 BR112017005314A BR112017005314A BR112017005314A2 BR 112017005314 A2 BR112017005314 A2 BR 112017005314A2 BR 112017005314 A BR112017005314 A BR 112017005314A BR 112017005314 A BR112017005314 A BR 112017005314A BR 112017005314 A2 BR112017005314 A2 BR 112017005314A2
Authority
BR
Brazil
Prior art keywords
imidazo
pyridine derived
derived health
inhibitors
health inhibitors
Prior art date
Application number
BR112017005314A
Other languages
English (en)
Inventor
Savory Edward
Patient Lee
Espensen Max
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of BR112017005314A2 publication Critical patent/BR112017005314A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

a presente invenção refere-se a um composto como apresentado na reivindicação 1, e o uso do mesmo em terapia.
BR112017005314A 2014-09-17 2015-09-17 inibidores de ssao derivados de imidazo[4,5-c]piridina BR112017005314A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1416446.1A GB201416446D0 (en) 2014-09-17 2014-09-17 New enzyme inhibitor compounds
PCT/GB2015/052690 WO2016042331A1 (en) 2014-09-17 2015-09-17 Imidazo[4,5-c]pyridine derived ssao inhibitors

Publications (1)

Publication Number Publication Date
BR112017005314A2 true BR112017005314A2 (pt) 2017-12-05

Family

ID=51869761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005314A BR112017005314A2 (pt) 2014-09-17 2015-09-17 inibidores de ssao derivados de imidazo[4,5-c]piridina

Country Status (15)

Country Link
US (1) US10065954B2 (pt)
EP (1) EP3194388B1 (pt)
JP (1) JP6556838B2 (pt)
CN (1) CN107074854B (pt)
AU (1) AU2015316610B2 (pt)
BR (1) BR112017005314A2 (pt)
CA (1) CA2961422A1 (pt)
DK (1) DK3194388T3 (pt)
ES (1) ES2745824T3 (pt)
GB (1) GB201416446D0 (pt)
HU (1) HUE045626T2 (pt)
IL (1) IL251164B (pt)
PL (1) PL3194388T3 (pt)
PT (1) PT3194388T (pt)
WO (1) WO2016042331A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201416446D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
CN108148066A (zh) * 2017-12-23 2018-06-12 广东赛博科技有限公司 含异丙哌嗪和哌嗪***类结构化合物、制备方法及其用途
CN107936028A (zh) * 2017-12-23 2018-04-20 广东赛博科技有限公司 一种哌嗪***类化合物、制备方法及其用途
CN108003170A (zh) * 2017-12-23 2018-05-08 广东赛博科技有限公司 含吗啉和哌嗪***类衍生物及其用途
CN108003167A (zh) * 2017-12-23 2018-05-08 广东赛博科技有限公司 乙丙哌嗪的哌嗪***结构化合物及其用途
CN107936026A (zh) * 2017-12-23 2018-04-20 广东赛博科技有限公司 ***类ssao抑制剂、制备方法及其用途
CN108084191A (zh) * 2017-12-23 2018-05-29 广东赛博科技有限公司 一种***类ssao抑制剂、制备方法及其用途
CN108084190A (zh) * 2017-12-23 2018-05-29 广东赛博科技有限公司 哌嗪***类ssao抑制剂、制备方法及其用途
CN108003169A (zh) * 2017-12-23 2018-05-08 广东赛博科技有限公司 一种含吗啉和哌嗪***类化合物及其用途
CN108164533A (zh) * 2017-12-23 2018-06-15 广东赛博科技有限公司 含胺基苯的哌嗪***结构的化合物及其用途
CN108084189A (zh) * 2017-12-23 2018-05-29 广东赛博科技有限公司 含氟苯和哌嗪***类化合物、制备方法及其用途
CN107936027A (zh) * 2017-12-23 2018-04-20 广东赛博科技有限公司 含哌嗪基和哌嗪***类结构化合物、制备方法及其用途
CN108003166A (zh) * 2017-12-23 2018-05-08 广东赛博科技有限公司 含哌嗪基和哌嗪***类结构化合物、制备方法及其用途
WO2021222308A1 (en) * 2020-04-28 2021-11-04 Metacrine, Inc. Ssao inhibitors for the treatment of disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038153A1 (en) * 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
KR20060073929A (ko) 2003-08-08 2006-06-29 라 졸라 파마슈티칼 컴파니 질환 치료에 유용한 세미카르바지드 민감성 아민옥시다제(ｓｓａｏ) 및 ｖａｐ-1 매개 유착의 억제제
WO2005023246A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
CN102232073B (zh) * 2008-09-16 2014-10-29 普罗克西梅根有限公司 Ssao活性抑制剂
JP5613671B2 (ja) * 2008-09-16 2014-10-29 プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． 新規化合物ｉｉ
US20120010188A1 (en) 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
US9593108B2 (en) 2009-04-06 2017-03-14 Ptc Therapeutics, Inc. Compounds and methods for antiviral treatment
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
IN2014DN01883A (pt) 2011-09-14 2015-05-15 Proximagen Ltd
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201404498D0 (en) * 2014-03-13 2014-04-30 Proximagen Ltd New compounds
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
GB201416446D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds

Also Published As

Publication number Publication date
DK3194388T3 (da) 2019-09-23
PT3194388T (pt) 2019-09-27
EP3194388A1 (en) 2017-07-26
ES2745824T3 (es) 2020-03-03
IL251164A0 (en) 2017-04-30
EP3194388B1 (en) 2019-08-14
IL251164B (en) 2020-10-29
GB201416446D0 (en) 2014-10-29
US10065954B2 (en) 2018-09-04
CN107074854B (zh) 2019-07-19
US20170362218A1 (en) 2017-12-21
PL3194388T3 (pl) 2019-12-31
JP6556838B2 (ja) 2019-08-07
AU2015316610B2 (en) 2019-05-30
JP2017528493A (ja) 2017-09-28
CN107074854A (zh) 2017-08-18
HUE045626T2 (hu) 2020-01-28
CA2961422A1 (en) 2016-03-24
WO2016042331A1 (en) 2016-03-24
AU2015316610A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
BR112017005314A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
CR20150462A (es) Inhibidores de erk y sus usos
AR089993A1 (es) Macrociclos peptidomimeticos
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112017020178A2 (pt) vacina estreptocócica
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EA201692554A1 (ru) Менингококковые вакцины
EP3167761A4 (en) Legged fixture, and leg adjuster and leg adjuster set for use in same
BR112017010471A2 (pt) compostos de di-hidropirimidin-2-ona e usos médicos dos mesmos
IL251166A0 (en) Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao
BR112017019337A2 (pt) tratamento de dor
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
BR112017027721A2 (pt) formulação de alta concentração
BR112016019893A2 (pt) composições de glicoproteína sialilada e seus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: BENEVOLENTAI CAMBRIDGE LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: BENEVOLENTAI CAMBRIDGE LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: PROXIMAGEN GROUP LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: PROXIMAGEN, LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time